1. Home
  2. Live Updates
  3. Axoguard nerve cap

Page 5 - Axoguard Nerve Cap News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axoguard nerve cap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axoguard Nerve Cap Today - Breaking & Trending Today

Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , South Korea , United Kingdom , Ted Joyce , Karen Zaderej , Exchange Commission , Axogen Inc , Soft Tissue Membrane , Core Accounts , Inactive Accounts , Nerve Graft , Avance Nerve Graft , Axoguard Nerve Connector , Axoguard Nerve Protector , Axoguard Nerve Cap , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Except Share , Per Share Amounts , Years Ended December , Except Per Share Amounts , Three Months Ended December , Year Ended December , Ended December , Months Ended September ,

AxoGen, inc (AXGN) Q3 2021 Earnings Call Transcript

AXGN earnings call for the period ending September 30, 2021. ....

United States , Kyle Rose Canaccord , Kyle Rose , Peter Mariani , Peterj Mariani , Canaccord Medtech , Anthony Petrone Jefferies , Erin Broderick , Karen Zaderej , Danielle Antalffy , Anthony Petrone , Hand Society Conference , American Society For Surgery Of The Hand , Us Pain Foundation , American Association Of Oral Maxillofacial Surgeons , Diagnostics Forum , Axogen Reports Third Quarter , Executive Vice President , Vice President And Chief Financial , Chief Executive Officer , Annual American Society , Annual American Association , Oral Maxillofacial , Breast Cancer Awareness Month , Biologics License Application , Avance Nerve Graft ,

AxoGen, inc (AXGN) Q2 2021 Earnings Call Transcript

AxoGen, inc (AXGN) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

San Francisco , United States , Karen Zaderej , Pete Mariani , Washington Nerve Institute , Washington University , Axogen Inc , Report Second Quarter , Results Conference , Executive Vice President , Chief Financial , Vice President , Chief Executive Officer , Nerve Matters , Annual Meeting , American Society , Hand Conference , Avance Nerve Graft , Axoguard Nerve Cap , சான் பிரான்சிஸ்கோ , ஒன்றுபட்டது மாநிலங்களில் , பீட் மரியானி , வாஷிங்டன் பல்கலைக்கழகம் , அறிக்கை இரண்டாவது காலாண்டு , முடிவுகள் மாநாடு , நிர்வாகி துணை ப்ரெஸிடெஂட் ,

(AXGN) - Recap: Axogen Q1 Earnings


52-week low: $7.65
Company Description
Axogen Inc is engaged in the science, development and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically proven and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.
 
Related Articles (AXGN) ....

United States , United Kingdom , South Korea , Axogen Inc , Company Description , Avance Nerve Graft , Axoguard Nerve Connector , Axoguard Nerve Protector , Axoguard Nerve Cap , Avive Soft Tissue , Axotouch Two Point Discriminator , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , தெற்கு கொரியா , நிறுவனம் விளக்கம் , அவன்ச நரம்பு ஒட்டு ,

Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
Axogen, Inc.February 18, 2021 GMT
ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study. 
Analysis of the REPOSE study’s 15-subject single arm pilot phase demonstrated that subjects experienced a clinically significant reduction in pain from baseline at each of the 3, 6, 9, and 12 month timepoints following surgical excision of the neuroma and placement of Axoguard Nerve Cap® (p 0.0001). Specifically, the study observed a mean reduction in pain of 69 points at 3 months and 80 points at 12 months as measured on the 100-point Visual Analog Scale (VAS). Additionally, subjects experienc ....

United States , United Kingdom , South Korea , Peter Mariani , Craig Thomajan , Karen Zaderej , Exchange Commission , Axogen Inc , Axoguard Nerve Cap , Visual Analog Scale , Physical Function , Sleep Disturbance , Pain Interference , Spain Intensity , Spain Behavior , Peripheral Nerve Surgeon , Austin Foot , Ankle Specialists , Subject Blinded Comparative Study , Symptomatic Neuroma , Recurrent End Neuroma Pain , Nerve Cap , Nerve Graft , Nerve Connector , Nerve Protector , Soft Tissue Membrane ,